Positive Phase 3 Trial Results for Wet AMD Treatment Announced

Essex Bio-Technology has reported successful Phase 3 clinical trial results for its investigational drug EB12-20145P (HLX04-O), targeting wet age-related macular degeneration. The study met its primary endpoint, demonstrating the drug's non-inferiority to ranibizumab in improving vision and exhibiting a favorable safety profile. These findings are expected to support future marketing authorization applications in international markets.